BIOR

Biora Therapeutics, Inc. (BIOR) | Rumor.io

Biora Therapeutics

BIOR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BIOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 6

The company has experienced significant dilution, with one investor reporting a 3-year investment of $60,000 reduced to $560 after several reverse stock splits (RS) and dilutions.
There are concerns about the company's financial health, with some investors predicting a further decline in value to $0.00 within a couple of weeks.
The company's delisting from the Nasdaq and potential bankruptcy have led to calls for the company's leadership, including CEO Adi, to suffer consequences for their actions.

Generated by AI

Sentiment

Of the messages about BIOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	53.59% +17.85
Bearish	—	—	—	46.41% -17.85

Bullish· Feb 28

Biora Therapeutics has shown promising results with its BT-600 data and secured funding from a partner, indicating potential for significant growth.
The company's technology has the potential to be a game-changer in treatments, making it a high-risk but potentially high-reward investment opportunity.
A buyout from a big pharma company or a squeeze on short interest could provide a significant catalyst for the stock's price to increase.

Bearish· Dec 30

The management of Biora Therapeutics, Inc. has been accused of making empty promises to investors and diluting shares, ultimately leading to bankruptcy.
The company's decision to file for Chapter 11 bankruptcy has been criticized as a scam that leaves shareholders with nothing.
Existing shareholders may face significant losses, including the potential for their shares to be wiped out, as the company has a history of reverse splits and dilution.

Generated by AI

Topics

Of the messages about BIOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	14.29%
Macro	—	—	—	21.43%
Earnings	—	—	—	0%
Controversies	—	—	—	42.86%
Announcements	—	—	—	21.43%
Analysts	—	—	—	0%

Earnings· Nov 10

Biora Therapeutics, Inc. (BIOR) reported a net loss of $43.7 million for the third quarter, with a net loss per share of $0.46, beating the consensus estimate.
The company generated $9.6 million in revenues during the third quarter, with $9.4 million coming from discontinued operations.
BIOR's earnings beat was expected by many, with some analysts predicting a positive outcome and others speculating about the potential for a partnership announcement to drive the stock higher.

Analysts· Oct 14

H.C. Wainwright initiated coverage of Progenity (PROG) with a Buy rating and a $4 price target.
Analyst Joseph Pantginis of H.C. Wainwright initiated coverage of Progenity with a Buy rating and a $4 price target.
The price target of $4 was set by H.C. Wainwright analyst Joseph Pantginis in his initiation of coverage of Progenity.

Announcements· Apr 1

Biora Therapeutics, Inc. ($BIOR) entered into definitive agreements for a $6 million registered direct offering, priced at $1.10 per share, with 5.5 million shares to be sold and warrants to purchase up to 5.5 million shares issued concurrently.
The offering is expected to close on or about April 3, 2024, subject to customary closing conditions, with H.C. Wainwright & Co. as the exclusive placement agent.
The registered direct offering is priced at-the-market under Nasdaq rules, with Biora Therapeutics issuing unregistered warrants to purchase up to 5.5 million shares at an exercise price of $1.10 per share.

Technical Analysis· Jan 11

$BIOR has a descending wedge that needs to break $7 for another big play.
The stock is showing a bull flag formation, indicating a potential continuation of the upward trend.
A triple bottom pattern is forming, which could indicate a higher low and a continuation of the upward trend.

Generated by AI

Community

Of the messages about BIOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	60.7%
Newcomers	—	—	—	39.3%

Regulars· Apr 1

The company is facing a significant dilution issue due to the recent registered direct offering, with the offering price being substantially higher than the net tangible book value per share.
The regulars are questioning the leadership of Adi Mohanty, with one of them asking why Adi didn't mention the earnings call LAST WEEK, and another one questioning Adi's past statement about the stock being undervalued.
The company has entered into a definitive agreement for the purchase and sale of 5.5 million shares at $1.10 per share, and will also issue unregistered warrants in a concurrent private placement.

Newcomers· Dec 1

Newcomers are excited about the potential for $BIOR to increase by 200-300% on FDA news, citing the company's recent success.
One newcomer has a mixed view on the stock's prospects, noting the company's high insider ownership at 50% and its broken afternoon price, but remains optimistic about its future.
Another newcomer is celebrating a profitable trade, having covered a short position in $VIEW and earning a significant profit, which was partly due to a successful trade in $BIOR.

Generated by AI

Also Discussed

Investors talking about BIOR also mention

#	Name	Attention
1	Vinco Ventures Inc.BBIG	0%+0
2	Aterian Inc.ATER	0%new
3	Longeveron Inc. Class A Common StockLGVN	0%0
4	METX - Meten Holding Group Ltd.	——
5	Prog Holdings Inc.PRG	0.01%new
6	GROM - Grom Social Enterprises, Inc.	——
7	Phunware, Inc.PHUN	0%0
8	Farmmi, Inc. Class A Ordinary SharesFAMI	0%0
9	Biofrontera Inc.BFRI	0%0
10	Bakkt Holdings, Inc. Class A Common StockBKKT	0.02%+0